Biopsy-Proven Immune Complex Glomerulonephritis Associated with Sunitinib in a Patient with a Gastrointestinal Stromal Tumor.
- Author:
Hankyu LEE
1
;
Hyang Rim LEE
;
Kook Hwan OH
;
Kyung Chul MOON
;
Curie AHN
;
Suhnggwon KIM
;
Yung Jue BANG
Author Information
1. Department of Internal Medicine, Eulji Hospital, Daejeon, Korea.
- Publication Type:Case Report
- Keywords:
Glomerulonephritis;
Sunitinib;
Gastrointestinal stromal tumor
- MeSH:
Antigen-Antibody Complex;
Carcinoma, Renal Cell;
Gastrointestinal Stromal Tumors;
Glomerulonephritis;
Humans;
Hypertension;
Indoles;
Protein-Tyrosine Kinases;
Proteinuria;
Pyrroles;
Thrombotic Microangiopathies
- From:Korean Journal of Nephrology
2010;29(5):644-649
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sunitinib, a multi-targeted tyrosine kinase inhibitor, is used for the treatment of renal cell carcinoma and gastrointestinal stromal tumors. Many adverse effects associated with sunitinib, including hypertension, proteinuria, and thrombotic microangiopathy, have been reported; however, the other forms of glomerulonephritis are very rare. We report a case of biopsy-confirmed immune complex glomerulonephritis in a patient with a gastrointestinal tumor who received sunitinib treatment. The proteinuria subsided partially after sunitinib was discontinued, but when the drug was reintroduced, it recurred.
